Please login to the form below

Not currently logged in
Email:
Password:

RSV

This page shows the latest RSV news and features for those working in and with pharma, biotech and healthcare.

GSK's pivotal TB vaccine could prevent millions of deaths

GSK's pivotal TB vaccine could prevent millions of deaths

In an analyst call earlier this year, GSK head of global vaccines Roger Connor said that the company is particularly excited about the three respiratory syncytial virus (RSV) vaccines coming through

Latest news

More from news
Approximately 2 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The previous licensing deal was for exclusive global rights to the phase 1‐ready RSV compound, AK0529 which is now in a phase 2 study.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    Company acquisition. Anti-viral therapies, lead compound AL-8176 an oral antiviral in phase II for infant RSV.

  • Pharma deals during September 2014 Pharma deals during September 2014

    Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    175. MicroDose Therapeutx / Teva. Acquisition. Acquisition of inhalation technology including MDT-637 for RSV (phase II).

  • Pharma deals during June 2013 Pharma deals during June 2013

    The deal brings to Teva a multi dose dry powder nebuliser technology and MDT-637, a low dose, small molecule, fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Dutch biotech Mucosis promotes Thomas Johnston to CEO Dutch biotech Mucosis promotes Thomas Johnston to CEO

    development and commercialisation of the Mimopath platform including our RSV vaccine candidate.". ... During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics